{"id":25711,"date":"2016-12-27T13:27:21","date_gmt":"2016-12-27T19:27:21","guid":{"rendered":"https:\/\/prensalibre-com-develop.go-vip.co\/guatevision\/?p=25711"},"modified":"2016-12-27T11:17:57","modified_gmt":"2016-12-27T17:17:57","slug":"farmaco-revolucionario-detiene-deterioro-cerebral-pacientes-esclerosis-multiple","status":"publish","type":"post","link":"https:\/\/prensalibre-com-develop.go-vip.co\/guatevision\/historico\/farmaco-revolucionario-detiene-deterioro-cerebral-pacientes-esclerosis-multiple","title":{"rendered":"El f\u00e1rmaco revolucionario que detiene el deterioro cerebral en pacientes con esclerosis m\u00faltiple"},"content":{"rendered":"<p>Redacci\u00f3n<\/p>\n<p>BBC Mundo<\/p>\n<figure id=\"attachment_25714\" aria-describedby=\"caption-attachment-25714\" style=\"width: 660px\" class=\"wp-caption alignnone\"><a href=\"http:\/\/ichef-1.bbci.co.uk\/news\/660\/cpsprodpb\/12260\/production\/_93063347_c0310127-multiple_sclerosis_patient-spl.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-25714 size-full\" src=\"https:\/\/prensalibre-com-develop.go-vip.co\/guatevision\/wp-content\/uploads\/2016\/12\/93063347_c0310127-multiple_sclerosis_patient-spl.jpg\" alt=\"Los s\u00edntomas de la EM incluyen fatiga, p\u00e9rdida de sensibilidad y fuerza en las extremidades, dificultades para coordinar los movimientos, y paulatinamente, discapacidad.\" width=\"660\" height=\"371\" srcset=\"https:\/\/prensalibre-com-develop.go-vip.co\/guatevision\/wp-content\/uploads\/sites\/2\/2016\/12\/93063347_c0310127-multiple_sclerosis_patient-spl.jpg 660w, https:\/\/prensalibre-com-develop.go-vip.co\/guatevision\/wp-content\/uploads\/sites\/2\/2016\/12\/93063347_c0310127-multiple_sclerosis_patient-spl.jpg?resize=300,169 300w, https:\/\/prensalibre-com-develop.go-vip.co\/guatevision\/wp-content\/uploads\/sites\/2\/2016\/12\/93063347_c0310127-multiple_sclerosis_patient-spl.jpg?resize=276,154 276w, https:\/\/prensalibre-com-develop.go-vip.co\/guatevision\/wp-content\/uploads\/sites\/2\/2016\/12\/93063347_c0310127-multiple_sclerosis_patient-spl.jpg?resize=260,146 260w, https:\/\/prensalibre-com-develop.go-vip.co\/guatevision\/wp-content\/uploads\/sites\/2\/2016\/12\/93063347_c0310127-multiple_sclerosis_patient-spl.jpg?resize=150,84 150w\" sizes=\"auto, (max-width: 660px) 100vw, 660px\" \/><\/a><figcaption id=\"caption-attachment-25714\" class=\"wp-caption-text\">Los s\u00edntomas de la EM incluyen fatiga, p\u00e9rdida de sensibilidad y fuerza en las extremidades, dificultades para coordinar los movimientos, y paulatinamente, discapacidad. SPL<\/figcaption><\/figure>\n<p><strong>En tres ensayos cl\u00ednicos con pacientes con escler\u00f3sis m\u00faltiple (EM) los m\u00e9dicos lograron frenar la progresi\u00f3n del da\u00f1o cerebral utilizando un f\u00e1rmaco<\/strong>.<\/p>\n<p>Ocrelizumab es la primera droga que funciona en la EM primaria progresiva, contra la que hasta el momento no se hab\u00eda hallado ning\u00fan tratamiento eficaz.<\/p>\n<p>Expertos describieron a la droga que altera el sistema inmunol\u00f3gico como <strong>un hito en el tratamiento<\/strong> de la esclerosis m\u00faltiple.<\/p>\n<ul>\n<li><a href=\"http:\/\/www.bbc.com\/mundo\/noticias-36499220\">El agresivo tratamiento que destruye el sistema inmunol\u00f3gico pero puede curar la esclerosis m\u00faltiple<\/a><\/li>\n<\/ul>\n<p>La Agencia de Alimentos y F\u00e1rmacos de EE.UU. y las autoridades sanitarias europeas evaluar\u00e1n ahora su eficacia y seguridad para autorizar su comercializaci\u00f3n.<\/p>\n<h3>Enfermedad incurable<\/h3>\n<p>La esclerosis m\u00faltiple est\u00e1 causada por una <strong>falla en el sistema inmunol\u00f3gico<\/strong> que confunde a una parte del cerebro con un invasor y lo ataca.<\/p>\n<figure id=\"attachment_25713\" aria-describedby=\"caption-attachment-25713\" style=\"width: 624px\" class=\"wp-caption alignnone\"><a href=\"http:\/\/ichef.bbci.co.uk\/news\/624\/cpsprodpb\/961D\/production\/_93092483_thinkstockphotos-462404779.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-25713 size-full\" src=\"https:\/\/prensalibre-com-develop.go-vip.co\/guatevision\/wp-content\/uploads\/2016\/12\/93092483_thinkstockphotos-462404779.jpg\" alt=\"El sistema inmunol\u00f3gico de una persona con EM destruye la mielina de las c\u00e9lulas nerviosas.\" width=\"624\" height=\"351\" srcset=\"https:\/\/prensalibre-com-develop.go-vip.co\/guatevision\/wp-content\/uploads\/sites\/2\/2016\/12\/93092483_thinkstockphotos-462404779.jpg 624w, https:\/\/prensalibre-com-develop.go-vip.co\/guatevision\/wp-content\/uploads\/sites\/2\/2016\/12\/93092483_thinkstockphotos-462404779.jpg?resize=300,169 300w, https:\/\/prensalibre-com-develop.go-vip.co\/guatevision\/wp-content\/uploads\/sites\/2\/2016\/12\/93092483_thinkstockphotos-462404779.jpg?resize=276,154 276w, https:\/\/prensalibre-com-develop.go-vip.co\/guatevision\/wp-content\/uploads\/sites\/2\/2016\/12\/93092483_thinkstockphotos-462404779.jpg?resize=260,146 260w, https:\/\/prensalibre-com-develop.go-vip.co\/guatevision\/wp-content\/uploads\/sites\/2\/2016\/12\/93092483_thinkstockphotos-462404779.jpg?resize=150,84 150w\" sizes=\"auto, (max-width: 624px) 100vw, 624px\" \/><\/a><figcaption id=\"caption-attachment-25713\" class=\"wp-caption-text\">El sistema inmunol\u00f3gico de una persona con EM destruye la mielina de las c\u00e9lulas nerviosas. THINKSTOCK<\/figcaption><\/figure>\n<p>El sistema inmunol\u00f3gico <strong>destruye la capa de prote\u00edna, llamada mielina, que cubre y protege las c\u00e9lulas nerviosas<\/strong>, y ayuda a enviar las se\u00f1ales el\u00e9ctricas desde el cerebro al resto del cuerpo.<\/p>\n<p>Esto provoca<strong> p\u00e9rdida de fuerza, dificultades para caminar, fatiga y visi\u00f3n borrosa.<\/strong><\/p>\n<ul>\n<li><a href=\"http:\/\/www.bbc.com\/mundo\/video_fotos\/2016\/01\/160120_video_esclerosis_multiple_lp\">El tratamiento contra el c\u00e1ncer que ha hecho volver a caminar a pacientes con esclerosis m\u00faltiple<\/a><\/li>\n<\/ul>\n<p>Los s\u00edntomas pueden empeorar, que es lo que se conoce como EM primaria progresiva, o pueden aparecer y desaparecer (remitente-recurrente).<\/p>\n<p><strong>Ambas formas son incurables<\/strong>, aunque existen tratamientos para la segunda.<\/p>\n<h3>Hito<\/h3>\n<p>Ocrelizumab mata a una parte del sistema inmunol\u00f3gico -las llamadas c\u00e9lulas B- que participan en el ataque la mielina.<\/p>\n<figure id=\"attachment_25712\" aria-describedby=\"caption-attachment-25712\" style=\"width: 624px\" class=\"wp-caption alignnone\"><a href=\"http:\/\/ichef-1.bbci.co.uk\/news\/624\/cpsprodpb\/E43D\/production\/_93092485_msbody.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-25712 size-full\" src=\"https:\/\/prensalibre-com-develop.go-vip.co\/guatevision\/wp-content\/uploads\/2016\/12\/93092485_msbody.jpg\" alt=\"La enfermedad, en sus dos formas, no tiene cura.\" width=\"624\" height=\"351\" srcset=\"https:\/\/prensalibre-com-develop.go-vip.co\/guatevision\/wp-content\/uploads\/sites\/2\/2016\/12\/93092485_msbody.jpg 624w, https:\/\/prensalibre-com-develop.go-vip.co\/guatevision\/wp-content\/uploads\/sites\/2\/2016\/12\/93092485_msbody.jpg?resize=300,169 300w, https:\/\/prensalibre-com-develop.go-vip.co\/guatevision\/wp-content\/uploads\/sites\/2\/2016\/12\/93092485_msbody.jpg?resize=276,154 276w, https:\/\/prensalibre-com-develop.go-vip.co\/guatevision\/wp-content\/uploads\/sites\/2\/2016\/12\/93092485_msbody.jpg?resize=260,146 260w, https:\/\/prensalibre-com-develop.go-vip.co\/guatevision\/wp-content\/uploads\/sites\/2\/2016\/12\/93092485_msbody.jpg?resize=150,84 150w\" sizes=\"auto, (max-width: 624px) 100vw, 624px\" \/><\/a><figcaption id=\"caption-attachment-25712\" class=\"wp-caption-text\">La enfermedad, en sus dos formas, no tiene cura. THINKSTOCK<\/figcaption><\/figure>\n<p>En 732 pacientes con EM primaria progresiva, el porcentaje que sufri\u00f3 un deterioro cay\u00f3 de 39% sin tratamiento a 33% con ocrelizumab.<\/p>\n<p>Aquellos que tomaron la droga tambi\u00e9n necesitaron <strong>menos tiempo para caminar una distancia de menos de 10 metros<\/strong> y un diagn\u00f3stico por im\u00e1genes mostr\u00f3 que <strong>perdieron menos neuronas<\/strong>.<\/p>\n<ul>\n<li><a href=\"http:\/\/www.bbc.com\/mundo\/video_fotos\/2014\/08\/140827_video_mujer_discapacitada_esclerosis_lp\">Vivir con esclerosis m\u00faltiple: &#8220;No hace falta seguir siendo invisible&#8221;<\/a><\/li>\n<\/ul>\n<p>En 1656 pacientes con EM remitente-recurrente, la probabilidad de sufrir una reca\u00edda se redujo de un 29% con otra droga a un 16% con ocrelizumab.<\/p>\n<p>&#8220;Los resultados de estos estudios tienen el potencial de cambiar c\u00f3mo tratamos la EM primaria progresiva y la remitente-recurrente&#8221;, se\u00f1al\u00f3 Gavin Giovannoni, profesor de la Escuela de Medicina y Odontolog\u00eda de Londres, quien particip\u00f3 en los ensayos.<\/p>\n<p>&#8220;<strong>Es una noticia muy importante<\/strong> (&#8230;). Es la primera vez que un tratamiento muestra potencial para reducir la progresi\u00f3n de la discapacidad para la EM primaria progresiva, lo cual<strong> trae muchas esperanzas para el futuro<\/strong>&#8220;, coment\u00f3 Aisling McMahon, director de ensayos cl\u00ednicos de la Sociedad de Esclerosis M\u00faltiple.<\/p>\n<p>Peter Calabresi, doctor de la Universidad John Hopkins en Baltimore, EE.UU. se refiri\u00f3 al nuevo tratamiento como un hito, pero advirti\u00f3 sobre la necesidad de estar <strong>atentos a los efectos colaterales de la droga.<\/strong><\/p>\n<p>Debilitar el sistema inmunol\u00f3gico aumenta el riesgo de infecci\u00f3n y de c\u00e1ncer.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>En 732 pacientes con EM primaria progresiva, el porcentaje que sufri\u00f3 un deterioro cay\u00f3 de 39% sin tratamiento a 33% con ocrelizumab.<\/p>\n","protected":false},"author":218,"featured_media":25714,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_hide_featured_image":false,"_jetpack_featured_image_duplicate_dismissed":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_post_was_ever_published":false},"categories":[],"etiqueta":[],"class_list":["post-25711","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>El f\u00e1rmaco Que detiene el deterioro cerebral con esclerosis m\u00faltiple<\/title>\n<meta name=\"description\" content=\"En 732 pacientes con EM primaria progresiva, el porcentaje que sufri\u00f3 un deterioro cay\u00f3 de 39% sin tratamiento a 33% con ocrelizumab.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/prensalibre-com-develop.go-vip.co\/guatevision\/historico\/farmaco-revolucionario-detiene-deterioro-cerebral-pacientes-esclerosis-multiple\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"El f\u00e1rmaco Que detiene el deterioro cerebral con esclerosis m\u00faltiple\" \/>\n<meta property=\"og:description\" content=\"En 732 pacientes con EM primaria progresiva, el porcentaje que sufri\u00f3 un deterioro cay\u00f3 de 39% sin tratamiento a 33% con ocrelizumab.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/prensalibre-com-develop.go-vip.co\/guatevision\/historico\/farmaco-revolucionario-detiene-deterioro-cerebral-pacientes-esclerosis-multiple\" \/>\n<meta property=\"og:site_name\" content=\"Guatevision\" \/>\n<meta property=\"article:published_time\" content=\"2016-12-27T19:27:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/prensalibre-com-develop.go-vip.co\/guatevision\/wp-content\/uploads\/sites\/2\/2016\/12\/93063347_c0310127-multiple_sclerosis_patient-spl.jpg?quality=82\" \/>\n\t<meta property=\"og:image:width\" content=\"660\" \/>\n\t<meta property=\"og:image:height\" content=\"371\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Redacci\u00f3n Guatevisi\u00f3n\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Redacci\u00f3n Guatevisi\u00f3n\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/prensalibre-com-develop.go-vip.co\\\/guatevision\\\/historico\\\/farmaco-revolucionario-detiene-deterioro-cerebral-pacientes-esclerosis-multiple#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/prensalibre-com-develop.go-vip.co\\\/guatevision\\\/historico\\\/farmaco-revolucionario-detiene-deterioro-cerebral-pacientes-esclerosis-multiple\"},\"author\":{\"name\":\"Redacci\u00f3n Guatevisi\u00f3n\",\"@id\":\"https:\\\/\\\/prensalibre-com-develop.go-vip.co\\\/guatevision\\\/#\\\/schema\\\/person\\\/7c26ea5ceee1b7266a573b2125e1c2aa\"},\"headline\":\"El f\u00e1rmaco revolucionario que detiene el deterioro cerebral en pacientes con esclerosis m\u00faltiple\",\"datePublished\":\"2016-12-27T19:27:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/prensalibre-com-develop.go-vip.co\\\/guatevision\\\/historico\\\/farmaco-revolucionario-detiene-deterioro-cerebral-pacientes-esclerosis-multiple\"},\"wordCount\":588,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/prensalibre-com-develop.go-vip.co\\\/guatevision\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/prensalibre-com-develop.go-vip.co\\\/guatevision\\\/historico\\\/farmaco-revolucionario-detiene-deterioro-cerebral-pacientes-esclerosis-multiple#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/prensalibre-com-develop.go-vip.co\\\/guatevision\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2016\\\/12\\\/93063347_c0310127-multiple_sclerosis_patient-spl.jpg\",\"keywords\":[\"BBCMundo\",\"deterioro cerebral\",\"esclerosis m\u00faltiple\",\"Salud\"],\"inLanguage\":\"es-GT\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/prensalibre-com-develop.go-vip.co\\\/guatevision\\\/historico\\\/farmaco-revolucionario-detiene-deterioro-cerebral-pacientes-esclerosis-multiple#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/prensalibre-com-develop.go-vip.co\\\/guatevision\\\/historico\\\/farmaco-revolucionario-detiene-deterioro-cerebral-pacientes-esclerosis-multiple\",\"url\":\"https:\\\/\\\/prensalibre-com-develop.go-vip.co\\\/guatevision\\\/historico\\\/farmaco-revolucionario-detiene-deterioro-cerebral-pacientes-esclerosis-multiple\",\"name\":\"El f\u00e1rmaco Que detiene el deterioro cerebral con esclerosis m\u00faltiple\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/prensalibre-com-develop.go-vip.co\\\/guatevision\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/prensalibre-com-develop.go-vip.co\\\/guatevision\\\/historico\\\/farmaco-revolucionario-detiene-deterioro-cerebral-pacientes-esclerosis-multiple#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/prensalibre-com-develop.go-vip.co\\\/guatevision\\\/historico\\\/farmaco-revolucionario-detiene-deterioro-cerebral-pacientes-esclerosis-multiple#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/prensalibre-com-develop.go-vip.co\\\/guatevision\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2016\\\/12\\\/93063347_c0310127-multiple_sclerosis_patient-spl.jpg\",\"datePublished\":\"2016-12-27T19:27:21+00:00\",\"description\":\"En 732 pacientes con EM primaria progresiva, el porcentaje que sufri\u00f3 un deterioro cay\u00f3 de 39% sin tratamiento a 33% con ocrelizumab.\",\"inLanguage\":\"es-GT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/prensalibre-com-develop.go-vip.co\\\/guatevision\\\/historico\\\/farmaco-revolucionario-detiene-deterioro-cerebral-pacientes-esclerosis-multiple\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es-GT\",\"@id\":\"https:\\\/\\\/prensalibre-com-develop.go-vip.co\\\/guatevision\\\/historico\\\/farmaco-revolucionario-detiene-deterioro-cerebral-pacientes-esclerosis-multiple#primaryimage\",\"url\":\"https:\\\/\\\/prensalibre-com-develop.go-vip.co\\\/guatevision\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2016\\\/12\\\/93063347_c0310127-multiple_sclerosis_patient-spl.jpg\",\"contentUrl\":\"https:\\\/\\\/prensalibre-com-develop.go-vip.co\\\/guatevision\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2016\\\/12\\\/93063347_c0310127-multiple_sclerosis_patient-spl.jpg\",\"width\":660,\"height\":371},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/prensalibre-com-develop.go-vip.co\\\/guatevision\\\/#website\",\"url\":\"https:\\\/\\\/prensalibre-com-develop.go-vip.co\\\/guatevision\\\/\",\"name\":\"Guatevision\",\"description\":\"\u00a1Enciende Lo Bueno!\",\"publisher\":{\"@id\":\"https:\\\/\\\/prensalibre-com-develop.go-vip.co\\\/guatevision\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/prensalibre-com-develop.go-vip.co\\\/guatevision\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es-GT\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/prensalibre-com-develop.go-vip.co\\\/guatevision\\\/#organization\",\"name\":\"Guatevision\",\"url\":\"https:\\\/\\\/prensalibre-com-develop.go-vip.co\\\/guatevision\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es-GT\",\"@id\":\"https:\\\/\\\/prensalibre-com-develop.go-vip.co\\\/guatevision\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/prensalibre-com-develop.go-vip.co\\\/guatevision\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2026\\\/04\\\/Diseno-sin-titulo.png\",\"contentUrl\":\"https:\\\/\\\/prensalibre-com-develop.go-vip.co\\\/guatevision\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2026\\\/04\\\/Diseno-sin-titulo.png\",\"width\":1000,\"height\":600,\"caption\":\"Guatevision\"},\"image\":{\"@id\":\"https:\\\/\\\/prensalibre-com-develop.go-vip.co\\\/guatevision\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/prensalibre-com-develop.go-vip.co\\\/guatevision\\\/#\\\/schema\\\/person\\\/7c26ea5ceee1b7266a573b2125e1c2aa\",\"name\":\"Redacci\u00f3n Guatevisi\u00f3n\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es-GT\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/30137a0ea5fbd7114184dc546048a84bb0a0138981443c3af84a9d824dffdd9b?s=96&d=mm&r=g6d36cd161df0dff3760fc313fe2275f7\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/30137a0ea5fbd7114184dc546048a84bb0a0138981443c3af84a9d824dffdd9b?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/30137a0ea5fbd7114184dc546048a84bb0a0138981443c3af84a9d824dffdd9b?s=96&d=mm&r=g\",\"caption\":\"Redacci\u00f3n Guatevisi\u00f3n\"},\"url\":\"https:\\\/\\\/prensalibre-com-develop.go-vip.co\\\/guatevision\\\/author\\\/redacciongtv\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"El f\u00e1rmaco Que detiene el deterioro cerebral con esclerosis m\u00faltiple","description":"En 732 pacientes con EM primaria progresiva, el porcentaje que sufri\u00f3 un deterioro cay\u00f3 de 39% sin tratamiento a 33% con ocrelizumab.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/prensalibre-com-develop.go-vip.co\/guatevision\/historico\/farmaco-revolucionario-detiene-deterioro-cerebral-pacientes-esclerosis-multiple","og_locale":"es_ES","og_type":"article","og_title":"El f\u00e1rmaco Que detiene el deterioro cerebral con esclerosis m\u00faltiple","og_description":"En 732 pacientes con EM primaria progresiva, el porcentaje que sufri\u00f3 un deterioro cay\u00f3 de 39% sin tratamiento a 33% con ocrelizumab.","og_url":"https:\/\/prensalibre-com-develop.go-vip.co\/guatevision\/historico\/farmaco-revolucionario-detiene-deterioro-cerebral-pacientes-esclerosis-multiple","og_site_name":"Guatevision","article_published_time":"2016-12-27T19:27:21+00:00","og_image":[{"width":660,"height":371,"url":"https:\/\/prensalibre-com-develop.go-vip.co\/guatevision\/wp-content\/uploads\/sites\/2\/2016\/12\/93063347_c0310127-multiple_sclerosis_patient-spl.jpg?quality=82","type":"image\/jpeg"}],"author":"Redacci\u00f3n Guatevisi\u00f3n","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Redacci\u00f3n Guatevisi\u00f3n","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/prensalibre-com-develop.go-vip.co\/guatevision\/historico\/farmaco-revolucionario-detiene-deterioro-cerebral-pacientes-esclerosis-multiple#article","isPartOf":{"@id":"https:\/\/prensalibre-com-develop.go-vip.co\/guatevision\/historico\/farmaco-revolucionario-detiene-deterioro-cerebral-pacientes-esclerosis-multiple"},"author":{"name":"Redacci\u00f3n Guatevisi\u00f3n","@id":"https:\/\/prensalibre-com-develop.go-vip.co\/guatevision\/#\/schema\/person\/7c26ea5ceee1b7266a573b2125e1c2aa"},"headline":"El f\u00e1rmaco revolucionario que detiene el deterioro cerebral en pacientes con esclerosis m\u00faltiple","datePublished":"2016-12-27T19:27:21+00:00","mainEntityOfPage":{"@id":"https:\/\/prensalibre-com-develop.go-vip.co\/guatevision\/historico\/farmaco-revolucionario-detiene-deterioro-cerebral-pacientes-esclerosis-multiple"},"wordCount":588,"commentCount":0,"publisher":{"@id":"https:\/\/prensalibre-com-develop.go-vip.co\/guatevision\/#organization"},"image":{"@id":"https:\/\/prensalibre-com-develop.go-vip.co\/guatevision\/historico\/farmaco-revolucionario-detiene-deterioro-cerebral-pacientes-esclerosis-multiple#primaryimage"},"thumbnailUrl":"https:\/\/prensalibre-com-develop.go-vip.co\/guatevision\/wp-content\/uploads\/sites\/2\/2016\/12\/93063347_c0310127-multiple_sclerosis_patient-spl.jpg","keywords":["BBCMundo","deterioro cerebral","esclerosis m\u00faltiple","Salud"],"inLanguage":"es-GT","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/prensalibre-com-develop.go-vip.co\/guatevision\/historico\/farmaco-revolucionario-detiene-deterioro-cerebral-pacientes-esclerosis-multiple#respond"]}]},{"@type":"WebPage","@id":"https:\/\/prensalibre-com-develop.go-vip.co\/guatevision\/historico\/farmaco-revolucionario-detiene-deterioro-cerebral-pacientes-esclerosis-multiple","url":"https:\/\/prensalibre-com-develop.go-vip.co\/guatevision\/historico\/farmaco-revolucionario-detiene-deterioro-cerebral-pacientes-esclerosis-multiple","name":"El f\u00e1rmaco Que detiene el deterioro cerebral con esclerosis m\u00faltiple","isPartOf":{"@id":"https:\/\/prensalibre-com-develop.go-vip.co\/guatevision\/#website"},"primaryImageOfPage":{"@id":"https:\/\/prensalibre-com-develop.go-vip.co\/guatevision\/historico\/farmaco-revolucionario-detiene-deterioro-cerebral-pacientes-esclerosis-multiple#primaryimage"},"image":{"@id":"https:\/\/prensalibre-com-develop.go-vip.co\/guatevision\/historico\/farmaco-revolucionario-detiene-deterioro-cerebral-pacientes-esclerosis-multiple#primaryimage"},"thumbnailUrl":"https:\/\/prensalibre-com-develop.go-vip.co\/guatevision\/wp-content\/uploads\/sites\/2\/2016\/12\/93063347_c0310127-multiple_sclerosis_patient-spl.jpg","datePublished":"2016-12-27T19:27:21+00:00","description":"En 732 pacientes con EM primaria progresiva, el porcentaje que sufri\u00f3 un deterioro cay\u00f3 de 39% sin tratamiento a 33% con ocrelizumab.","inLanguage":"es-GT","potentialAction":[{"@type":"ReadAction","target":["https:\/\/prensalibre-com-develop.go-vip.co\/guatevision\/historico\/farmaco-revolucionario-detiene-deterioro-cerebral-pacientes-esclerosis-multiple"]}]},{"@type":"ImageObject","inLanguage":"es-GT","@id":"https:\/\/prensalibre-com-develop.go-vip.co\/guatevision\/historico\/farmaco-revolucionario-detiene-deterioro-cerebral-pacientes-esclerosis-multiple#primaryimage","url":"https:\/\/prensalibre-com-develop.go-vip.co\/guatevision\/wp-content\/uploads\/sites\/2\/2016\/12\/93063347_c0310127-multiple_sclerosis_patient-spl.jpg","contentUrl":"https:\/\/prensalibre-com-develop.go-vip.co\/guatevision\/wp-content\/uploads\/sites\/2\/2016\/12\/93063347_c0310127-multiple_sclerosis_patient-spl.jpg","width":660,"height":371},{"@type":"WebSite","@id":"https:\/\/prensalibre-com-develop.go-vip.co\/guatevision\/#website","url":"https:\/\/prensalibre-com-develop.go-vip.co\/guatevision\/","name":"Guatevision","description":"\u00a1Enciende Lo Bueno!","publisher":{"@id":"https:\/\/prensalibre-com-develop.go-vip.co\/guatevision\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/prensalibre-com-develop.go-vip.co\/guatevision\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es-GT"},{"@type":"Organization","@id":"https:\/\/prensalibre-com-develop.go-vip.co\/guatevision\/#organization","name":"Guatevision","url":"https:\/\/prensalibre-com-develop.go-vip.co\/guatevision\/","logo":{"@type":"ImageObject","inLanguage":"es-GT","@id":"https:\/\/prensalibre-com-develop.go-vip.co\/guatevision\/#\/schema\/logo\/image\/","url":"https:\/\/prensalibre-com-develop.go-vip.co\/guatevision\/wp-content\/uploads\/sites\/2\/2026\/04\/Diseno-sin-titulo.png","contentUrl":"https:\/\/prensalibre-com-develop.go-vip.co\/guatevision\/wp-content\/uploads\/sites\/2\/2026\/04\/Diseno-sin-titulo.png","width":1000,"height":600,"caption":"Guatevision"},"image":{"@id":"https:\/\/prensalibre-com-develop.go-vip.co\/guatevision\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/prensalibre-com-develop.go-vip.co\/guatevision\/#\/schema\/person\/7c26ea5ceee1b7266a573b2125e1c2aa","name":"Redacci\u00f3n Guatevisi\u00f3n","image":{"@type":"ImageObject","inLanguage":"es-GT","@id":"https:\/\/secure.gravatar.com\/avatar\/30137a0ea5fbd7114184dc546048a84bb0a0138981443c3af84a9d824dffdd9b?s=96&d=mm&r=g6d36cd161df0dff3760fc313fe2275f7","url":"https:\/\/secure.gravatar.com\/avatar\/30137a0ea5fbd7114184dc546048a84bb0a0138981443c3af84a9d824dffdd9b?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/30137a0ea5fbd7114184dc546048a84bb0a0138981443c3af84a9d824dffdd9b?s=96&d=mm&r=g","caption":"Redacci\u00f3n Guatevisi\u00f3n"},"url":"https:\/\/prensalibre-com-develop.go-vip.co\/guatevision\/author\/redacciongtv"}]}},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/prensalibre-com-develop.go-vip.co\/guatevision\/wp-content\/uploads\/sites\/2\/2016\/12\/93063347_c0310127-multiple_sclerosis_patient-spl.jpg","_links":{"self":[{"href":"https:\/\/prensalibre-com-develop.go-vip.co\/guatevision\/wp-json\/wp\/v2\/posts\/25711","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/prensalibre-com-develop.go-vip.co\/guatevision\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/prensalibre-com-develop.go-vip.co\/guatevision\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/prensalibre-com-develop.go-vip.co\/guatevision\/wp-json\/wp\/v2\/users\/218"}],"replies":[{"embeddable":true,"href":"https:\/\/prensalibre-com-develop.go-vip.co\/guatevision\/wp-json\/wp\/v2\/comments?post=25711"}],"version-history":[{"count":0,"href":"https:\/\/prensalibre-com-develop.go-vip.co\/guatevision\/wp-json\/wp\/v2\/posts\/25711\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/prensalibre-com-develop.go-vip.co\/guatevision\/wp-json\/wp\/v2\/media\/25714"}],"wp:attachment":[{"href":"https:\/\/prensalibre-com-develop.go-vip.co\/guatevision\/wp-json\/wp\/v2\/media?parent=25711"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/prensalibre-com-develop.go-vip.co\/guatevision\/wp-json\/wp\/v2\/categories?post=25711"},{"taxonomy":"etiqueta","embeddable":true,"href":"https:\/\/prensalibre-com-develop.go-vip.co\/guatevision\/wp-json\/wp\/v2\/etiqueta?post=25711"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}